Genmab — November 2017
-
Tænker jeg os Bulder,
-
PR og muligheden for at søge på interimdata - så bliver det vist ikke meget mere høj-prioriteret fra FDAs side, når vi taler 1.line
-
Jeg tænker på at får vi Japan salget i gang i f.eks. 1. halvdel af december, så vil det da bidrage positivt til en eventuel blød opjustering. Det vil godt nok komme efter q3 regnskabet, men det vil blive opfattet positivt. Sidste år kom der en sen opjustering pga. noget lignende.
-
Another death related to allogenic CAR-T cell therapy https://european-biotechnology.com/up-to-date/latest-news/news/another-death-related-to-allogenic-car-t-cell-therapy.html
-
-
While the detailed ph III ALCYONE frontline MM data was not among the abstracts published yesterday, note that the late breaking abstracts are not yet available on the ASH website; ie abstracts covering data which were not fully available by the general abstract submission deadline (2 August). As Genmab and JnJ did not announce top-line results from the ph III ALCYONE study before 24 August, the abstract could not be accepted within the general abstract submission deadline.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

